Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor – Clinical outcome and laboratory observations

Benny Sørensen; Jørgen Ingerslev

doi:10.1160/TH10-01-0019

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(06): 1275-1276
DOI: 10.1160/TH10-01-0019

Letters to the Editor

Schattauer GmbH

Platelet infusion supports recombinant factor VIIa in a patient with severe haemophilia A and inhibitor – Clinical outcome and laboratory observations

Authors

Benny Sørensen

¹Haemostasis Research Unit, Centre for Haemophilia and Thrombosis, Guy’s and St Thomas’s NHS Foundation Trust & King’s College London School of Medicine, London, UK

²Center for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Denmark
Jørgen Ingerslev

²Center for Haemophilia and Thrombosis, Aarhus University Hospital, Skejby, Denmark

Abstract

Full Text

References

References
1 Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26: 425-432.
2 Pruthi RK, Mathew P, Valentino LA. et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-732.
3 Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100: 557-562.
4 Shapiro AD, Gilchrist GS, Hoots WK. et al. Prospective, randomised trial of two doses of rFVIIa (Novo-Seven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
5 Schulman S, Lindstedt M, Alberts KA. et al. Recombinant factor VIIa in multiple surgery. Thromb Haemost 1994; 71: 154.
6 Martinowitz U, Livnat T, Zivelin A. et al. Concomitant infusion of low doses of rFVIIa and FEIBA in severe haemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent haemostatic effect and synergistically enhances thrombin generation. J Thromb Haemost 2005 03. (Suppl 1): Abstract P0637.
7 Butenas S, Brummel KE, Bouchard BA. et al. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 01: 1158-1160.
8 Monroe DM, Hoffman M, Oliver JA. et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-547.
9 Gerotziafas GT, Chakroun T, Depasse F. et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91: 977-985.
10 Carr ME Jr, Martin EJ, Kuhn JG. et al. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 2003; 89: 803-811.
11 Campbell RA, Fischer TH, Wolberg AS. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation. Br J Haematol 2007; 138: 82-93.
12 Sørensen B, Johansen P, Christiansen K. et al. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 01: 551-558.
13 Sørensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 (Suppl. 01) 1-6.